Phase 1/2 Study of REGN5458 in Adult Patients With Relapsed or Refractory Multiple Myeloma

Active:	Yes
Cancer Type:	Multiple Myeloma	NCT ID:	NCT03761108
Trial Phases:	Phase I Phase II	Protocol IDs:	R5458-ONC-1826 (primary) NCI-2019-02952 2018-003188-78
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Regeneron Pharmaceuticals, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT03761108

Summary

The main purpose of this study is to learn about the safety of REGN5458 and to find out
what is the best dose of REGN5458 to give to patients with multiple myeloma. An
additional purpose is to look for any signs that REGN5458 can treat cancer.

The study is looking at several other research questions, including:

- Side effects that may be experienced by people receiving REGN5458

- How REGN5458 works in the body

- How much REGN5458 is present in the blood

- How REGN5458 may work to treat cancer

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.